Unique ID issued by UMIN | UMIN000013610 |
---|---|
Receipt number | R000015856 |
Scientific Title | A study on the safety of concentrated liquid diet containing pectin administered by gravity administration via naso-gastric tube |
Date of disclosure of the study information | 2014/04/15 |
Last modified on | 2015/09/15 12:16:00 |
A study on the safety of concentrated liquid diet containing pectin administered by gravity administration via naso-gastric tube
A study on the safety of gravity administration of concentrated liquid diet containing pectin
A study on the safety of concentrated liquid diet containing pectin administered by gravity administration
A study on the safety of concentrated liquid diet containing pectin administered by gravity administration via naso-gastric tube
A study on the safety of gravity administration of concentrated liquid diet containing pectin
A study on the safety of concentrated liquid diet containing pectin administered by gravity administration
Japan |
Patients requiring the nutritional management using naso-gastric tube
Gastroenterology |
Others
NO
To investigate the incidence of gastrointestinal symptoms during the gravity administration of novel liquid diet, HINE E-gel, via naso-gastric tube and to observe the effects of nutritional supplementation of the diet
Safety
Incidence of gastrointestinal symptoms
Total number of defecation and frequency of diarrhea
Presence or absence of vomiting, nausea, and abdominal distention
Frequency of antiflatulent usage
Nutritional parameters (blood albumin, total blood protein, blood trans-thyretin, and body weight)
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Food |
The HINE E-gel is given via a naso-gastric tube (12 Fr) by the gravity administration for a week. The daily dose calculated by the Harris-Benedict equation is divided into three administrations which are given morning, noon, and evening.
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients who are 20 years or older at the date of informed consent
2)Patients who receive the transnasal nutrition with the catheter inserted into the stomach
3)Patients who are able to provide a voluntary consent after receiving the sufficient verbal or written explanation for participation in the study
1)Patients who might have an allergy to the study product or other food
2)Patients who take gastric acid secretion inhibitor
3)Patients who might not be able to participate in the study because of complications such as hepatic failure, kidney failure, and cardiac disease
4)Female patients who are pregnant, lactating, or potentially pregnant
5)Patients who are deemed unsuitable for inclusion in the study for any other reason by the investigator
50
1st name | |
Middle name | |
Last name | Satoshi Goshi |
Joetsu general hospital
gastrointestinal medicine
616, Daidofukuda, Joetsu-shi, Niigata, Japan
025-524-3000
goshi@joetsu-hp.jp
1st name | |
Middle name | |
Last name | Satoshi Goshi |
Joetsu general hospital
gastrointestinal medicine
616, Daidofukuda, Joetsu-shi, Niigata, Japan
025-524-3000
goshi@joetsu-hp.jp
Joetsu general hospital
Otsuka Pharmaceutical Factory, Inc.
Profit organization
Japan
NO
2014 | Year | 04 | Month | 15 | Day |
Published
Completed
2014 | Year | 04 | Month | 20 | Day |
2014 | Year | 05 | Month | 15 | Day |
2015 | Year | 12 | Month | 31 | Day |
2015 | Year | 12 | Month | 31 | Day |
2016 | Year | 01 | Month | 30 | Day |
2016 | Year | 03 | Month | 31 | Day |
2014 | Year | 04 | Month | 02 | Day |
2015 | Year | 09 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015856